<![CDATA[Capivasertib and Emerging Options in the Post–CDK4/6 Inhibitor Setting]]>

ConferencecapivasertibfulvestrantNeutral

AI Analysis

Summary

Dr. Erica L. Mayer from Dana-Farber Cancer Institute discusses capivasertib plus fulvestrant in the competitive landscape for treating HR-positive, HER2-negative advanced breast cancer in the post-CDK4/6 inhibitor setting.

Importance:3/10

Sentiment:

0.00

breast cancerhormone receptor positiveHER2-negativeCDK4/6 inhibitorscombination therapy

Related Companies

$INTI

Read the original article

Published by Cancer Network on September 1, 2026 6:30 PM

Read Original